N-[2-(2,5-dioxoimidazolidin-4-yl)benzyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide | 676606-44-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-[2-(2,5-dioxoimidazolidin-4-yl)benzyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
• 英文别名: N-[[2-(2,5-dioxoimidazolidin-4-yl)phenyl]methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
• CAS: 676606-44-3
• 化学式: C₂₈H₂₄N₄O₄
• 分子量: 480.523
• InChiKey: DAOQSJKLXBSCNV-UHFFFAOYSA-N

物化性质

• 密度：
  1.308±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  36
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  109
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
  申请人：——

  公开号：US20040067996A1

  公开（公告）日：2004-04-08

  The present application describes novel hydantoin derivatives of formula (I): 1 or pharmaceutically acceptable salt or prodrug forms thereof, wherein L, Z 0 , R 1 , R 4 , R 5 , and R 11 are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-&agr; converting enzyme (TACE), aggrecanase, or a combination thereof.

  本申请描述了式（I）的新颖咪唑烷二酮衍生物：1或其药用盐或前药形式，其中L、Z0、R1、R4、R5和R11如本规范中定义，这些衍生物可作为基质金属蛋白酶（MMP）、TNF-α转化酶（TACE）、聚集素酶的抑制剂，或者两者的组合。
• HYDANTOIN DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-ALPHA CONVERTING ENZYME (TACE)
  申请人：Bristol-Myers Squibb Company

  公开号：EP1546109A2

  公开（公告）日：2005-06-29
• EP1546109A4
  申请人：——

  公开号：EP1546109A4

  公开（公告）日：2005-11-09
• US7041693B2
  申请人：——

  公开号：US7041693B2

  公开（公告）日：2006-05-09
• [EN] HYDANTOIN DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-ALPHA CONVERTING ENZYME (TACE)<br/>[FR] DERIVES D'HYDANTOINE EN TANT QU'INHIBITEURS DE METALLOPROTEINASES MATRICIELLES ET/OU DE L'ENZYME DE CONVERSION DE TNF-ALPHA (TACE)
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2004033632A2

  公开（公告）日：2004-04-22

  The present application describes novel hydantoin derivatives of formula (I) or pharmaceutically acceptable salt or prodrug forms thereof, wherein L, Z0, R1, R4, R5, and R11 are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-a converting enzyme (TACE), aggrecanase, or a combination thereof.